stockportfolio.pro
Stocks / EYPT vs TNDM
EYPT vs TNDM
EyePoint, Inc. and Tandem Diabetes Care, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| EyePoint, Inc. (EYPT) | Tandem Diabetes Care, Inc. (TNDM) | |
|---|---|---|
| Market cap | $1.0B | $1.1B |
| Revenue (latest FY) | $31.37M | $1.01B |
| Net income (latest FY) | $-231.96M | $-204.71M |
| Revenue growth (5y CAGR) | -1.8% | 15.3% |
| Net margin | -739.4% | -20.2% |
| Return on equity | -75.8% | -131.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EYPT — free Open TNDM — freeFrequently asked questions
Which is bigger, EYPT or TNDM?
Tandem Diabetes Care, Inc. is larger by market capitalization — $1.1B versus $1.0B.
Which grows faster, EYPT or TNDM?
Over the last five fiscal years, Tandem Diabetes Care, Inc. grew revenue faster — 15.3%/yr versus -1.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.